[go: up one dir, main page]

MX2022012073A - Metodos para el diagnostico y el tratamiento del cancer metastasico. - Google Patents

Metodos para el diagnostico y el tratamiento del cancer metastasico.

Info

Publication number
MX2022012073A
MX2022012073A MX2022012073A MX2022012073A MX2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A
Authority
MX
Mexico
Prior art keywords
methods
metastatic cancer
diagnosis
treatment
mirna
Prior art date
Application number
MX2022012073A
Other languages
English (en)
Inventor
John Lewis
Konstantin Stoletov
Lian Willetts
Original Assignee
Entos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entos Pharmaceuticals Inc filed Critical Entos Pharmaceuticals Inc
Publication of MX2022012073A publication Critical patent/MX2022012073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Se describen los métodos para diagnosticar y tratar el cáncer metastásico en un sujeto. Los métodos implican detectar o modular la expresión de al menos uno de Kif3b, ACTB, SRPK1, TMEM229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, ARNmi 130b, ARNmi 374b o ARNmi 122 en una muestra biológica del sujeto.
MX2022012073A 2016-06-14 2018-12-13 Metodos para el diagnostico y el tratamiento del cancer metastasico. MX2022012073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2932910A CA2932910A1 (en) 2016-06-14 2016-06-14 Methods for diagnosing and treating metastatic cancer

Publications (1)

Publication Number Publication Date
MX2022012073A true MX2022012073A (es) 2022-10-18

Family

ID=60655897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015474A MX2018015474A (es) 2016-06-14 2017-06-14 Metodos para el diagnostico y el tratamiento del cancer metastasico.
MX2022012073A MX2022012073A (es) 2016-06-14 2018-12-13 Metodos para el diagnostico y el tratamiento del cancer metastasico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015474A MX2018015474A (es) 2016-06-14 2017-06-14 Metodos para el diagnostico y el tratamiento del cancer metastasico.

Country Status (8)

Country Link
US (2) US11236331B2 (es)
EP (1) EP3468564A4 (es)
JP (2) JP7306829B2 (es)
CN (1) CN109562121A (es)
AU (2) AU2017285726B2 (es)
CA (2) CA2932910A1 (es)
MX (2) MX2018015474A (es)
WO (1) WO2017214726A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304988B2 (en) * 2018-01-24 2022-04-19 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)
US20210251963A1 (en) * 2018-09-06 2021-08-19 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
CN117187375B (zh) * 2023-09-12 2024-06-18 上海谱希和光基因科技有限公司 Kdelr3生物标志物在诊断高度近视中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE3938907C2 (de) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten
FR2814349B1 (fr) 2000-09-27 2002-12-06 Salomon Sa Sac a dos
CN101300348A (zh) 2005-09-02 2008-11-05 东丽株式会社 肾癌诊断、肾癌患者预后预测用的组合物及方法
JP5435529B2 (ja) 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
WO2007056604A2 (en) 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US20140342946A1 (en) * 2011-12-31 2014-11-20 Moni Abraham Kuriakose Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
WO2014151465A1 (en) 2013-03-15 2014-09-25 Board Of Regents, The University Of Texas System Brain-specific gene signature of tumor cells
WO2016002844A1 (ja) 2014-07-04 2016-01-07 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤

Also Published As

Publication number Publication date
CN109562121A (zh) 2019-04-02
JP2019525903A (ja) 2019-09-12
AU2023203737A1 (en) 2023-07-06
EP3468564A1 (en) 2019-04-17
EP3468564A4 (en) 2020-07-29
WO2017214726A1 (en) 2017-12-21
JP7306829B2 (ja) 2023-07-11
US20220112498A1 (en) 2022-04-14
US11236331B2 (en) 2022-02-01
AU2017285726A1 (en) 2019-01-24
CA3027430A1 (en) 2017-12-21
US12421514B2 (en) 2025-09-23
CA2932910A1 (en) 2017-12-14
JP2023123748A (ja) 2023-09-05
US20190177727A1 (en) 2019-06-13
AU2023203737B2 (en) 2024-08-29
AU2017285726B2 (en) 2023-03-16
MX2018015474A (es) 2019-06-06

Similar Documents

Publication Publication Date Title
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
SV2018005677A (es) Mutaciones puntuales en cancer resistente a trk y metodos relacionados con las mismas
MX2018001351A (es) Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cancer hematologico.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
BR112017023821A2 (pt) moduladores de k-ras
CR20160132A (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
BR112017020002A2 (pt) Combinação de inibidor de hdac e anticorpo anti- pd-1 para o tratamento de câncer
BR112014018592A2 (pt) composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112016024789A2 (pt) métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
PL3523639T3 (pl) Odczynniki wykrywające i układy elektrod do elementów diagnostycznych testów wieloanalitowych oraz sposoby ich zastosowania
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
MX2022012073A (es) Metodos para el diagnostico y el tratamiento del cancer metastasico.
WO2017127731A8 (en) Nmr methods and systems for the rapid detection of bacteria
MX2019003035A (es) Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
WO2016133449A9 (en) Detection and treatment of malignant tumours in the cns
BR112018003928A2 (pt) métodos para o tratamento de doenças
BR112018009463A2 (pt) ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
WO2015153948A3 (en) Microtentacle imaging in patient tumor samples
MX2017012553A (es) Compuestos espirociclicos.